Shopping Cart
Remove All
Your shopping cart is currently empty
TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $36 | In Stock | In Stock | |
| 5 mg | $77 | In Stock | In Stock | |
| 10 mg | $117 | In Stock | In Stock | |
| 25 mg | $222 | In Stock | In Stock | |
| 50 mg | $397 | In Stock | In Stock | |
| 100 mg | $619 | In Stock | In Stock | |
| 500 mg | $1,280 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $84 | In Stock | In Stock |
| Description | TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β. |
| Targets&IC50 | PI3Kδ:235 nM, PI3Kγ:83 nM |
| In vitro | In human umbilical vein endothelial cells, TG100-115 (10 μM) did not affect cell proliferation and VEGF-stimulated ERK phosphorylation, but blocked other vascular endothelial growth factor (VEGF) signaling pathways, such as VE-calmodulin phosphorylation, and thus inhibited the overall increase in the level of VE-calmodulin induced by VEGF. TG100-115 (0.125-10 μM) also inhibited FGF-stimulated Akt phosphorylation.The inhibitory effect of TG100-115 on PI3Kα/β was weak (IC50: 1.2/1.3 mM).TG100-115 inhibited vascular endothelial growth factor-regulated phosphorylation of p70S6 and mTOR kinase. |
| In vivo | In human umbilical vein endothelial cells, TG100-115 (10 μM) did not affect cell proliferation and VEGF-stimulated ERK phosphorylation, but blocked other vascular endothelial growth factor (VEGF) signaling pathways, such as VE-calmodulin phosphorylation, and thus inhibited the overall increase in the level of VE-calmodulin induced by VEGF. TG100-115 (0.125-10 μM) also inhibited FGF-stimulated Akt phosphorylation.The inhibitory effect of TG100-115 on PI3Kα/β was weak (IC50: 1.2/1.3 mM).TG100-115 inhibited vascular endothelial growth factor-regulated phosphorylation of p70S6 and mTOR kinase. |
| Kinase Assay | PI3K assays: Forty mL of reaction buffer (20 mM Tris/4 mM MgCl2/10 mM NaCl, pH 7.4) containing 50 mM D-myo-phosphatidylinositol 4,5-bisphosphate substrate and the desired PI3K isoform are aliquoted to 96-well plates; kinase concentrations are 250-500 ng/well, such that linear kinetics are achieved over 90 min. TG100-115 is then added as 2.5 mL of a DMSO stock to final concentration range of 100 mM to 1 nM. Reactions are initiated by addition of 10 mL of ATP to a final concentration of 3 mM, and after 90 min, 50 mL of Kinase-Glo reagent added to quantify residual ATP levels; luminosity is measured using an Ultra 384 instrument. Control reactions omitting either TG100-115 or substrate are also performed. IC50 values are derived from experimental data by nonlinear curve fitting using Prism Version 4. |
| Cell Research | Cells plated in 96-well cluster plates (5 × 103 cells/well) are cultured in assay medium (containing 0.5% serum and 50 ng/ml VEGF) in the presence or absence of TG100-115, and cell numbers are quantified by XTT assay 24, 48, or 72 hours late(Only for Reference) |
| Molecular Weight | 346.34 |
| Formula | C18H14N6O2 |
| Cas No. | 677297-51-7 |
| Smiles | Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1 |
| Relative Density. | 1.516 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 40 mg/mL (115.49 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.77 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.